The US Food and Drug Administration (FDA) has approved label changes for Sublocade (buprenorphine extended-release), ...

Indivior (INDV) announced that the FDA has approved label changes for Sublocade including a rapid initiation protocol and alternative injection ...

The FDA has approved label changes for once-monthly Sublocade, helping to reduce possible barriers to treatment initiation ...

Indivior PLC, a global leader in addiction treatment, announced that the US Food and Drug Administration (FDA) has approved label changes for Sublocade including a rapid initiation protocol and ...

Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has approved label changes for SUBLOCADE® including a rapid ...

Health care providers can now administer Sublocade subcutaneously into the thigh, buttock, or the back of the upper arm, in addition to the abdomen.

Indivior said the U.S. Food and Drug Administration approved label changes for its opioid-dependence treatment Sublocade, including a rapid initiation protocol and alternative injection sites.

Indivior Plc (NASDAQ:INDV) stock plunged following the company’s fiscal year 2025 guidance that fell short of Street ...

Pharmaceutical giant Indivior said on Monday that the US Food and Drug Administration has approved label changes for its ...

Indivior is committed to empowering patients ... do not alter the well-established safety profile or the efficacy of SUBLOCADE and the medication continues to offer an effective treatment option ...

Q4 2024 Management View The CEO highlighted that 2024 ended with SUBLOCADE achieving 20% net revenue growth despite challenges, including competition in the U.S. long-acting injectable (LAI) market ...